Clinical trials: Respiratory Diseases
Non Small Cell Lung Cancer (NSCLC)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent.
- Trial name
- ARCHER 1042 (NCT01465802)
- Testing
- Dacomitinib, Doxycycline, Probiotic
- Where
- 81 sites in United States, South Korea
- Volunteers
- 236 people
- Sponsor
- Pfizer
Rhinitis, Allergic
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis.
- Conditions
- Rhinitis, Allergic, Perennial
- Trial name
- NCT00524836
- Testing
- levocetirizine dihydrochloride
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Idiopathic Pulmonary Fibrosis
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients…
- Trial name
- NCT04614441
- Testing
- OFEV®
- Where
- 26 sites in Taiwan
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
This phase II randomised, double blind, placebo controlled, multicentre trial is designed to assess the efficacy and safety of continuous icotinib plus chemotherapy versus chemotherapy alone in patients who have progressed after…
- Trial name
- NCT01707329
- Testing
- Chemotherapy, Icotinib+chemotherapy
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Lung Cancer, Non-Small Cell
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
This phase II study is a single-arm, two-stage, multicentre study to determine the clinical activity of lapatinib in combination with pemetrexed in patients with Non-Small Cell Lung Cancer (NSCLC) who have received one prior…
- Trial name
- NCT00528281
- Testing
- Lapatinib, Pemetrexed
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Mycoplasma Pneumoniae Pneumonia
Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia
Mycoplasma pneumoniae pneumonia in children is one of the major diseases in children's respiratory department in China, but there are still large clinical unmet needs.
- Trial name
- NCT04296383
- Testing
- Azithromycin plus Xiyanping injection, Azithromycin
- Volunteers
- 450 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Lung Cancer (Non-Small Cell)
A Phase II Study of SKB571 in Patients With Lung Cancer
This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT07230405
- Testing
- SKB571 for injection
- Where
- 2 sites in China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Idiopathic Pulmonary Fibrosis
Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Main purpose -To explore the safety and tolerance of human umbilical cord mesenchymal stem cells in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05468502
- Testing
- Human umbilical cord mesenchymal stem cell injection
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Shanghai Life Science & Technology
Asthma
An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Asthma is a chronic inflammatory disease of airways and lungs that results in hyper-reactivity and clinically relevant episodes of wheezing.
- Trial name
- NCT03478657
- Testing
- ELLIPTA DPI, Ease of use questionnaires
- Where
- 19 sites in United States, Canada
- Volunteers
- 222 people
- Sponsor
- GlaxoSmithKline
Infections, Respiratory, Fever
Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals
Operational project to compare clinician collected nasopharyngeal (NP) samples to patient-obtained tongue, nasal and mid-turbinate (MT) samples in the detection of SARS-CoV-2 in an outpatient clinic setting
- Conditions
- Infections, Respiratory, Fever, Cough
- Trial name
- NCT04321369
- Testing
- Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals
- Where
- United States
- Volunteers
- 530 people
- Sponsor
- UnitedHealth Group
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
This is a randomized, blinded, positive-controlled study to evaluate the immunogenicity and safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, in population aged 18 years old and above（negative antibody against…
- Trial name
- NCT05663086
- Testing
- One dose group, Two doses group, Aged 18-59 years
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Common Cold
Iota-Carrageenan Nasal Spray in Common Cold
The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the…
- Trial name
- NCT01944631
- Testing
- Iota-Carrageenan
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic…
- Trial name
- KEYNOTE B36 (NCT04892472)
- Testing
- NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
- Where
- 24 sites in United States
- Volunteers
- 15 people
- Sponsor
- NovoCure GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.